These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 31343420)

  • 61. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
    Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
    Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ovarian Combined Serous Borderline Tumor/Low-grade Serous Carcinoma and Mesonephric-like Lesion: Report of 2 Cases With New Observations.
    Nilforoushan N; Liu L; Finkelman BS; Andersen J; Liu Y; James J; Hung CF; Wu TC; Vang R; Xing D
    Int J Gynecol Pathol; 2023 Mar; 42(2):182-191. PubMed ID: 35348533
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population.
    Hannibal CG; Vang R; Junge J; Frederiksen K; Kjaerbye-Thygesen A; Andersen KK; Tabor A; Kurman RJ; Kjaer SK
    Gynecol Oncol; 2014 Aug; 134(2):267-73. PubMed ID: 24924123
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparative study of BRAF gene mutations in ovarian serous tumors by immunohistochemistry and DNA sequencing.
    Liu YY; Wang QP; Liu FF; Zhu HT; He QZ
    J BUON; 2021; 26(3):670-676. PubMed ID: 34268919
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.
    Singer G; Oldt R; Cohen Y; Wang BG; Sidransky D; Kurman RJ; Shih IeM
    J Natl Cancer Inst; 2003 Mar; 95(6):484-6. PubMed ID: 12644542
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Low-grade serous carcinoma detected from intraoperative peritoneal washings: Cytological findings and detection of KRAS mutation.
    Yamamoto E; Warigaya K; Kinoshita Y; Yamamoto A; Murata SI
    Cancer Rep (Hoboken); 2022 Oct; 5(10):e1676. PubMed ID: 35801373
    [TBL] [Abstract][Full Text] [Related]  

  • 67. KRAS/BRAF Analysis in Ovarian Low-Grade Serous Carcinoma Having Synchronous All Pathological Precursor Regions.
    Nakamura K; Nakayama K; Ishibashi T; Ishikawa N; Ishikawa M; Katagiri H; Minamoto T; Sato E; Sanuki K; Yamashita H; Iida K; Sultana R; Kyo S
    Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128903
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis.
    Ayhan A; Kurman RJ; Yemelyanova A; Vang R; Logani S; Seidman JD; Shih IeM
    Am J Surg Pathol; 2009 Aug; 33(8):1220-4. PubMed ID: 19461510
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Biomolecular pathogenesis of borderline ovarian tumors: focusing target discovery through proteogenomics.
    Vergara D; Tinelli A; Martignago R; Malvasi A; Chiuri VE; Leo G
    Curr Cancer Drug Targets; 2010 Feb; 10(1):107-16. PubMed ID: 20088785
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators.
    Seidman JD; Kurman RJ
    Hum Pathol; 2000 May; 31(5):539-57. PubMed ID: 10836293
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases.
    Parker RL; Clement PB; Chercover DJ; Sornarajah T; Gilks CB
    Int J Gynecol Pathol; 2004 Jul; 23(3):265-72. PubMed ID: 15213603
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes.
    Russell SE; McCluggage WG
    J Pathol; 2004 Jun; 203(2):617-9. PubMed ID: 15141374
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Molecular characteristics of low-grade serous carcinoma in effusions.
    Doutel D; Davidson B; Nitschke Pettersen IK; Torgunrud A
    Cytopathology; 2023 Mar; 34(2):99-105. PubMed ID: 36609991
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Mutation analysis of papillary tubal hyperplasia associated with ovarian atypical proliferative serous tumor and low-grade serous carcinoma.
    Huang WC; Tsai CC; Wei MC; Kuo KT
    Am J Obstet Gynecol; 2013 Aug; 209(2):e6-8. PubMed ID: 23711666
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mucosal Proliferations in Completely Examined Fallopian Tubes Accompanying Ovarian Low-grade Serous Tumors: Neoplastic Precursor Lesions or Normal Variants of Benign Mucosa?
    Wolsky RJ; Price MA; Zaloudek CJ; Rabban JT
    Int J Gynecol Pathol; 2018 May; 37(3):262-274. PubMed ID: 28700429
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).
    Singer G; Shih IeM; Truskinovsky A; Umudum H; Kurman RJ
    Int J Gynecol Pathol; 2003 Jan; 22(1):37-41. PubMed ID: 12496696
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases.
    Smith Sehdev AE; Sehdev PS; Kurman RJ
    Am J Surg Pathol; 2003 Jun; 27(6):725-36. PubMed ID: 12766576
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern.
    Lee SH; Kim H; Kim WY; Han HS; Lim SD; Kim WS; Kim S; Hwang TS
    Pathol Int; 2013 May; 63(5):252-9. PubMed ID: 23714252
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The mutational frequency of BRAF and KRAS in low-grade serous testicular neoplasms-a case series.
    Gwiti P; Vereczkey I; Cundell D; Aslam S; Clench T; Csernák E; Götzer K; Braybrooke J; Sohail M; Melegh Z
    Histopathology; 2017 Nov; 71(5):686-692. PubMed ID: 28543997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.